TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25056569
Drug: Broad-spectrum micronutrient
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum micronutrient treatment
Study: 18572041
Drug: TLC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC diet with 0.5 cups of soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Study: 11879257
Drug: Antacid (30-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (30-ml dose of magnesium hydroxide/aluminium hydroxide)
Study: 10999119
Drug: TRH study
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH study in Group 3 (18 patients) with baseline TSH 5 to 10 mu IU/ml and exaggerated TSH response to TRH
Study: 6113074
Drug: Clobazam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (30 to 80 mg/day)
Study: 6113074
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 to 40 mg/day)
Study: 31102650
Drug: Buccal film
Normalized name: Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal film containing microdoses of midazolam (30 μg)
Study: 31102650
Drug: Buccal solution
Normalized name: POLICRESULEN 720 mg in 1 mL BUCCAL SOLUTION [ALBOTHYL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal solution of midazolam
Study: 26495770
Drug: Slow titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow titration of sertraline
Study: 26495770
Drug: Regular titration
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular titration of sertraline
Study: 9279219
Drug: Nebulized glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glutathione (GSH) 600 mg with 4 ml of 0.9% sodium chloride
Study: 9279219
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical saline solution)
Study: 3268179
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/Kg)
Study: 3268179
Drug: Meperidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1.5 mg/Kg)
Study: 3268179
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of morphine and meperidine
Study: 29482033
Drug: In-treatment cotinine
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment cotinine decreases
Study: 11239659
Drug: Digoxin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (1 mg) injected intra-amniotically 24 hours before the procedure
Study: 7845827
Drug: Digoxin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (1 mg)
Study: 9663724
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 28 days plus clarithromycin 500 mg b.d. for 7 days (Group A)
Study: 9663724
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 28 days plus clarithromycin 500 mg b.d. for 14 days (Group B)
Study: 7819689
Drug: Steroids only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids only (14 patients, 63.6%)
Study: 7819689
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and high-dose gamma globulin (4 patients)
Study: 7819689
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and splenectomy (2 patients)
Study: 7819689
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and immunosuppressive therapy (2 patients)
Study: 7819689
Drug: Initial prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial prednisone course (1-5 mg/kg/day)
Study: 7819689
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (4 patients, 18.2%)
Study: 4035228
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg/day
Study: 2978324
Drug: Pizotifen 1.5
Normalized name: Pizotifen 1.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 1.5 mg/day
Study: 8245085
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (n = 25)
Study: 8245085
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n = 31)
Study: 8245085
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for undisplaced fractures (n = 10)
Study: 3545844
Drug: Amoxicillin twice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin twice daily (60 mg/kg per day for 10 days)
Study: 3545844
Drug: Amoxicillin thrice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin thrice daily (60 mg/kg per day for 10 days)
Study: 3545844
Drug: Amoxicillin twice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin twice daily
Study: 3545844
Drug: Amoxicillin thrice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin thrice daily
Study: 3545844
Drug: Amoxicillin twice
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin twice daily and thrice daily
Study: 25441408
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg/day, increasing to 50 mg/day if minimal toxicity)
Study: 25441408
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 loading dose, then 250 mg/m2/week)
Study: 22507365
Drug: Interferential laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential laser therapy (n=100)
Study: 22507365
Drug: Conventional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laser therapy (n=100)
Study: 17513190
Drug: Active gel
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gel (lidocaine 20 mg/g)
Study: 7863833
Drug: Alendronate, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 20 mg/day for 6 months
Study: 21812261
Drug: Madopar (basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar (basic treatment) + BHG
Study: 21812261
Drug: Madopar (basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar (basic treatment) + Placebo
Study: 15496639
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg daily for 6 days
Study: 12966817
Drug: Manually guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually guided exposure therapy in virtual environments
Study: 1929099
Drug: Estriol vaginal
Normalized name: estriol Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol vaginal cream
Study: 1929099
Drug: Trazodone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone and Estriol vaginal cream
Study: 19713253
Drug: Repetitive paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive paravertebral injections with a mixture of 10 mL 0.25% bupivacaine and 40 mg methylprednisolone acetate every 48 h for a week
Study: 19713253
Drug: Repetitive paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive paravertebral injections with local anesthetics and steroids
Study: 19713253
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (paravertebral and standard therapy)
Study: 17124578
Drug: Terbinafine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 150 mg daily for 6 days
Study: 15225946
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g with codeine 60 mg
Study: 15225946
Drug: Placebo (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vitamin C 50 mg)
Study: 11172189
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with supplemental oxygen and no ventilatory support
Study: 21233425
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements and parental counseling
Study: 20420791
Drug: Toprel 100
Normalized name: metoprolol succinate 100 MG [Toprol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toprel 100 mg
Study: 20420791
Drug: Topamax 100
Normalized name: Topamax 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topamax 100 mg
Study: 17084803
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 or 20 mg/day)
Study: 17084803
Drug: Lutein +
Normalized name: Lutein + Kale
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein + Zeaxanthin (10 or 20 mg/day)
Study: 17084803
Drug: Zeaxanthin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zeaxanthin (10 or 20 mg/day)
Study: 12141769
Drug: Antibiotic packing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic packing (cotton gauze strips with polymyxin‐B‐sulfate and oxytetracycline ointment)
Study: 12141769
Drug: Antibiotic-free packing
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-free packing (polyvinyl acetate sponge and cotton gauze strips with sea‐salt ointment)
Study: 10199248
Drug: Active epidural
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active epidural analgesic paste
Study: 2304838
Drug: Project nurse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Project nurse intervention involving daily hospital visits, coordination of discharge planning, and home visits post-discharge.
Study: 6992902
Drug: Salbutamol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (6 mg/day)
Study: 31187424
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg IV followed by 0.5 µg/kg/h infusion during surgery)
Study: 31187424
Drug: Saline (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (same doses as DEX)
Study: 22829349
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spontaneous pushing plus perineal massage
Study: 19948625
Drug: Aripiprazole (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5, 10, or 15 mg/day)
Study: 11772231
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy administered for six months after surgery for Dukes C colon cancer
Study: 11772231
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy for advanced CRC
Study: 3148145
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg triazolam on nights N3, N4, N5
Study: 3148145
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg triazolam on nights N3, N4, N5
Study: 21092614
Drug: Electrical acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical acupuncture stimulation therapy combined with pelvic floor muscle therapy (PFMT)
Study: 22366878
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (80% of maximum) twice weekly for 10 weeks
Study: 12162755
Drug: Filgrastim (granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (granulocyte colony‐stimulating factor, G‐CSF)
Study: 2540141
Drug: Progestin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin (20 mg tid medroxyprogesterone acetate)
Study: 2540141
Drug: Estrogen (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (1.25 mg bid conjugated equine estrogens)
Study: 30695422
Drug: Muxiang Shunqi
Normalized name: Tumuxiang (Inula Helenium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muxiang Shunqi Pill (MSP), 6 g each time, three times per day, taken 30 min after dinner for 4 weeks
Study: 30695422
Drug: Mosapride Tablet
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride Tablet (MT), 5 mg each time, three times per day, taken 30 min before dinner for 4 weeks
Study: 23083839
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg (additional dose)
Study: 15261707
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or venlafaxine
Study: 11292002
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 microg/kg b.i.d.) + naltrexone (25 mg b.i.d.)
Study: 9022118
Drug: 2.0% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% dorzolamide (three times daily)
Study: 9022118
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol (twice daily)
Study: 9022118
Drug: 2.0% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% dorzolamide (twice daily) added to 0.5% timolol
Study: 7939393
Drug: Loxiglumide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (1200 mg orally)
Study: 30646253
Drug: ASSIP intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASSIP intervention (3 manual-based therapy sessions followed by regular personalized letters over 24 months)
Study: 26480931
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (DXM) 40 mg/d for 4 days
Study: 26480931
Drug: Prednisone (PDN)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PDN) 1.0 mg/kg daily for 4 weeks
Study: 24670122
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 200 mg daily for 12 weeks
Study: 24670122
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 400 mg daily for 12 weeks
Study: 24670122
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 600 mg daily for 12 weeks
Study: 24670122
Drug: Grape seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape seed extract (GSE) 800 mg daily for 12 weeks
Study: 18622420
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and peripheral stem-cell reinfusion
Study: 18622420
Drug: Using the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the catheter for both stem-cell apheresis and high-dose chemotherapy
Study: 18622420
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of total parenteral nutrition (TPN)
Study: 31302440
Drug: ECT (Electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT (Electroconvulsive Therapy)
Study: 11031332
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS; 400 microg, twice daily)
Study: 11031332
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (twice daily)
Study: 1468091
Drug: Cefadroxil monohydrate
Normalized name: Cefadroxil Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil monohydrate (30 mg/kg QD or 15 mg/kg BID)
Study: 3740024
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte gut lavage solution (old, n=105)
Study: 29393079
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (sterile 90% ethanol)
Study: 24796048
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (acupuncture, moxibustion, and modified Mojie tablet)
Study: 24796048
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (gestrinone 2.5 mg, once a day, twice a week)
Study: 24796048
Drug: Other groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other groups (acupuncture‐moxibustion and combined therapy)
Study: 21934156
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection targeting certain months (e.g., May)
Study: 18647523
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 8 grams daily
Study: 18647523
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (GSH) 1.2 grams daily
Study: 11164155
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neoadjuvant hormonal treatment (NHT)
Study: 11164155
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of neoadjuvant hormonal treatment (NHT)
Study: 9200377
Drug: Dual regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual regimen (omeprazole 0.6 mg/kg twice a day + amoxicillin 30 mg/kg twice a day)
Study: 9200377
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen (dual regimen + clarithromycin 15 mg/kg twice a day)
Study: 9200377
Drug: Active ulcers
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ulcers treatment
Study: 8477407
Drug: apomorphine injection
Normalized name: apomorphine Injectable Solution
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apomorphine injection (first and second injections)
Study: 8477407
Drug: apomorphine injection
Normalized name: apomorphine Injectable Solution
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apomorphine injection (second injection administered 10 or 80 min after first)
Study: 8477407
Drug: apomorphine injection
Normalized name: apomorphine Injectable Solution
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apomorphine injection (second administration)
Study: 3630589
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg‐1 diazepam orally with 100 ml of water 2 h before surgery (Group 100)
Study: 3630589
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg‐1 diazepam with 50 ml of water 2 h before surgery (Group 50)
Study: 25851421
Drug: HG broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: HG broccoli diet (400 g per week for 12 weeks)
Study: 25851421
Drug: Standard broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard broccoli diet (400 g per week for 12 weeks)
Study: 21114369
Drug: Sildenafil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (40 mg oral dose)
Study: 21114369
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1, alprostadil 200 ng · kg(‐1) · min(‐1) intravenous infusion)
Study: 19683591
Drug: SFC+LTRA (pranlukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC+LTRA (pranlukast 450 mg daily)
Study: 19683591
Drug: SFC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC therapy alone
Study: 15223852
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg flutamide once daily
Study: 15223852
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg flutamide twice daily
Study: 15223852
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg flutamide 3 times daily
Study: 15223852
Drug: Flutamide at
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide at 500 mg daily
Study: 11422007
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg single dose
Study: 9639751
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg ethinyl estradiol (EE)
Study: 9639751
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg ethinyl estradiol (EE)
Study: 8481662
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside (3.0 g/m2 for < 60 years; 1.0 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Study: 8481662
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose cytosine arabinoside (1.0 g/m2 for < 60 years; 0.5 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Study: 8481662
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose cytosine arabinoside
Study: 3318445
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 1,200 mg
Study: 23922258
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy (VT)
Study: 31619350
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no vibration therapy)
Study: 30033595
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg once or twice daily
Study: 23072079
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (conventional acupuncture at Tianshu, Zusanli, Shangjuxu, Sanyinjiao, Taichong with electric stimulation at bilateral Tianshu), 3-4 treatments per week for 4 weeks.